Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s evaluation that “Post-treatment acute exacerbation of hepatitis B” is supported is consistent with the FDA label warnings and patient counseling for SYMTUZA in HBV/HIV-1 coinfected patients after discontinuation.
Category Scores
Accurate Statements
Post-treatment acute exacerbation of hepatitis B is supported by the SYMTUZA label.
Label 5.1 states severe acute exacerbations of hepatitis B may occur with discontinuation of SYMTUZA in patients coinfected with HIV-1 and HBV and recommends close clinical and laboratory follow-up for at least several months; Label 17 reiterates this in patient counseling and advises not to discontinue without informing a healthcare provider.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is explicitly supported in the provided label sections and includes monitoring/counseling context; no contradictory or missing safety-critical elements were asserted in the response.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement